Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Buy by StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Oramed Pharmaceuticals in a research note on Monday, September 9th.

Oramed Pharmaceuticals Stock Down 2.5 %

Shares of NASDAQ:ORMP traded down $0.06 during trading on Friday, hitting $2.35. The stock had a trading volume of 77,568 shares, compared to its average volume of 137,984. The firm’s fifty day moving average is $2.40 and its 200 day moving average is $2.44. The company has a market capitalization of $95.81 million, a PE ratio of 9.04 and a beta of 1.77. Oramed Pharmaceuticals has a 12 month low of $1.67 and a 12 month high of $3.67.

Oramed Pharmaceuticals (NASDAQ:ORMP) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.21. Equities research analysts expect that Oramed Pharmaceuticals will post 0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Oramed Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ORMP. Murchinson Ltd. grew its holdings in Oramed Pharmaceuticals by 23.2% in the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company’s stock valued at $4,369,000 after purchasing an additional 320,495 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Oramed Pharmaceuticals in the second quarter valued at about $40,000. Renaissance Technologies LLC raised its stake in shares of Oramed Pharmaceuticals by 89.0% during the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Oramed Pharmaceuticals by 52.1% during the second quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 10,774 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Oramed Pharmaceuticals during the 1st quarter valued at approximately $68,000. 12.73% of the stock is owned by institutional investors and hedge funds.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.